259 related articles for article (PubMed ID: 23751259)
1. A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
El-Hage N; Dever SM; Podhaizer EM; Arnatt CK; Zhang Y; Hauser KF
AIDS; 2013 Sep; 27(14):2181-90. PubMed ID: 23751259
[TBL] [Abstract][Full Text] [Related]
2. Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Arnatt CK; Falls BA; Yuan Y; Raborg TJ; Masvekar RR; El-Hage N; Selley DE; Nicola AV; Knapp PE; Hauser KF; Zhang Y
Bioorg Med Chem; 2016 Nov; 24(22):5969-5987. PubMed ID: 27720326
[TBL] [Abstract][Full Text] [Related]
3. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
[TBL] [Abstract][Full Text] [Related]
4. A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates.
Kim S; Hahn YK; Podhaizer EM; McLane VD; Zou S; Hauser KF; Knapp PE
J Neuroinflammation; 2018 Oct; 15(1):285. PubMed ID: 30305110
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
Huang B; Wang H; Zheng Y; Li M; Kang G; Barreto-de-Souza V; Nassehi N; Knapp PE; Selley DE; Hauser KF; Zhang Y
J Med Chem; 2021 Jun; 64(11):7702-7723. PubMed ID: 34027668
[TBL] [Abstract][Full Text] [Related]
6. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR
Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
9. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia.
Turchan-Cholewo J; Dimayuga FO; Ding Q; Keller JN; Hauser KF; Knapp PE; Bruce-Keller AJ
J Neurosci Res; 2008 Jul; 86(9):2100-10. PubMed ID: 18338799
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
12. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
14. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
15. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines.
El-Hage N; Wu G; Wang J; Ambati J; Knapp PE; Reed JL; Bruce-Keller AJ; Hauser KF
Glia; 2006 Jan; 53(2):132-46. PubMed ID: 16206161
[TBL] [Abstract][Full Text] [Related]
17. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
Gramegna P; Latronico T; Branà MT; Di Bari G; Mengoni F; Belvisi V; Mascellino MT; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
PLoS One; 2011; 6(12):e28499. PubMed ID: 22174822
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
19. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
[TBL] [Abstract][Full Text] [Related]
20. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
